Guides manufacturers who are evaluating and/or seeking competitive intelligence on new drug launch candidates to fully understand current access, reimbursement dynamics and inform strategy. ZHI proprietary syndicated sources are leveraged to analyze managed care trends and issues for a specific therapeutic class.
Obtain a comprehensive 360° analysis of the access environment to enable launch coverage success including payer management, prescriber implications, and competitive messaging
Use the most actionable data to help key internal stakeholders navigate the evolving access marketplace including Brand, Payer Marketing, Analytics, Contracting, and Senior Leadership
Compare current payer landscape for similar products to understand the dynamics that matter most
Understand how future payer trends impact decision-making and drug launch planning
Identify how new drugs or generics will affect the current market
Understand current and future utilization management hurdles and opportunities, by category
Benchmark existing brand strategies against anticipated drug launch strategy
Compiled from proprietary, syndicated ZHI sources and reflecting the most up-to-date managed care trends for a designated therapeutic class, this unique combination of data, secondary market research, and payer activity data will help you gain a complete payer perspective. Where appropriate, results also account for anticipated new market entrants, and shifts to generic products.